EuroIntervention PCRonline - Connecting with the community

Randomised Trials 2017

1. DRUG-ELUTING STENTS

1.1 - DRUG-ELUTING STENTS VS BARE METAL STENTS

1.2 - COMPARISONS DRUG-ELUTING STENTS

1.3 - DES FOR CTO

1.4 - WITH OR WITHOUT ON-SITE CARDIAC SURGERY

1.5 - IVUS IS ANGIOGRAPHY-GUIDED DES

1.6 - VASCULAR CLOSURE DEVICE

1.7 - ROUTINE CORONARY ANGIOGRAPHY AFTER PCI

2. PCI FOR STEMI

2.1 - FIBRINOLYSIS VS PCI

2.2 - DES VS BMS

2.3 - DES VS DES

2.4 - EES VS SES

2.5 - GP IIB/IIIA

2.6 - DIRECT THROMBIN INHIBITORS

2.7 - CULPRIT VS TOTAL REVASCULARISATION

2.8 - THROMBECTOMY ASPIRATION

2.9 - PRE-CONDITIONING

2.10 - CELL THERAPY

2.11 - HYPOTHERMIA

2.12 - PRETREATMENT PPCI

3. STENTS FOR BIFURCATION LESIONS

3.1 - STENTS

4. STENT THROMBOSIS

4.1 - STENTS

5. IN-STENT RESTENOSIS

6. RADIAL VS FEMORAL APPROACH

7. REVASCULARISATION STRATEGY: PCI VS CABG

7.1 - PCI VS CABG: MV DISEASE

7.2 - PCI VS CABG: LAD DISEASE

7.3 - PCI VS CABG: LEFT MAIN DISEASE

8. EARLY INVASIVE VS EARLY CONSERVATIVE STRATEGY ACS

8.1 - TRIALS

9. FFR AND PCI

10. PREVENTION OF THROMBOTIC COMPLICATIONS DURING PCI

10.1 - DURATION DUAL ANTIPLATELET TREATMENT

10.2 - CLOPIDOGREL / ABCIXIMAB

10.3 - BIVALIRUDIN

10.4 - CANGRELOR

10.5 - PRASUGREL

10.6 - CILOSTAZOL

10.7 - OTAMIXABAN

10.8 - RANOLAZINE

10.9 - PLATELET REACTIVITY

11. AORTIC BALLOON COUNTERPULSATION

12. PREVENTION CONTRAST-INDUCED NEPHROPATHY

12.1 - TRIALS

13. PERCUTANEOUS TREATMENT FOR STRUCTURAL HEART DISEASE

13.1 - TAVI AND MITRAL CLIP

13.2 - CLOSURE FORAMEN OVALE

13.3 - CLOSURE LEFT ATRIAL APPENDAGE

13.4 - CLOSURE VENTRICULAR SEPTAL DEFECT

14. RENAL DENERVATION